Literature DB >> 8748668

The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse--implications for psychosis.

M L Carlsson1.   

Abstract

The present study has shown that a subthreshold dose of the uncompetitive N-methyl-D-aspartate (NMDA) antagonist MK-801, combined with a subthreshold dose of LSD, produces marked locomotor stimulation in monoamine-depleted mice. Likewise, MK-801, as well as the muscarine receptor antagonist atropine and the alpha-adrenoceptor agonist clonidine, were found to interact synergistically with the putative 5-HT2 receptor agonist UH-232 to produce locomotor activation in monoamine-depleted mice. All these responses were effectively blocked by the highly selective 5-HT2A receptor antagonist MDL 100,907. On the other hand, MDL 100,907 did not antagonize the hyperactivity response produced by clonidine given in combination with MK-801 or atropine in monoamine-depleted mice, nor the response produced by the mixed DA receptor agonist apomorphine, underlining the selectivity in the antagonistic action of MDL 100,907. Furthermore, MDL 100,907 attenuated the hyperactivity produced in intact mice by such disparate agents as MK-801, atropine or the DA uptake inhibitor GBR 12,909. A putative "permissive" role of the 5-HT2 receptor in the context of psychomotor activation is discussed, as well as its possible importance as target for antipsychotic therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8748668     DOI: 10.1007/bf01276460

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  11 in total

Review 1.  Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia.

Authors:  D C Javitt
Journal:  Hillside J Clin Psychiatry       Date:  1987

Review 2.  Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease.

Authors:  M Carlsson; A Carlsson
Journal:  Trends Neurosci       Date:  1990-07       Impact factor: 13.837

3.  Synergistic interactions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice.

Authors:  M Carlsson; A Svensson; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-06       Impact factor: 3.000

4.  Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms.

Authors:  R Tandon; J E Shipley; J F Greden; N A Mann; W H Eisner; J A Goodson
Journal:  Schizophr Res       Date:  1991 Jan-Feb       Impact factor: 4.939

5.  The non-competitive NMDA antagonists MK-801 and PCP, as well as the competitive NMDA antagonist SDZ EAA494 (D-CPPene), interact synergistically with clonidine to promote locomotion in monoamine-depleted mice.

Authors:  M Carlsson; A Svensson
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

6.  Synergistic interactions between the NMDA antagonist dizocilpine and the preferential dopamine autoreceptor antagonists (+)-AJ 76 and (+)-UH 232 with regard to locomotor stimulation in monoamine-depleted mice.

Authors:  A Svensson; M Carlsson; A Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1991

7.  The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate.

Authors:  N A Anis; S C Berry; N R Burton; D Lodge
Journal:  Br J Pharmacol       Date:  1983-06       Impact factor: 8.739

8.  Differential locomotor interactions between dopamine D1/D2 receptor agonists and the NMDA antagonist dizocilpine in monoamine-depleted mice.

Authors:  A Svensson; A Carlsson; M L Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1992

9.  5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine.

Authors:  C J Schmidt; G M Fadayel; C K Sullivan; V L Taylor
Journal:  Eur J Pharmacol       Date:  1992-11-13       Impact factor: 4.432

10.  Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia.

Authors:  J S Kim; H H Kornhuber; W Schmid-Burgk; B Holzmüller
Journal:  Neurosci Lett       Date:  1980-12       Impact factor: 3.046

View more
  6 in total

Review 1.  Modulation of ligand-gated ion channels by antidepressants and antipsychotics.

Authors:  Gerhard Rammes; Rainer Rupprecht
Journal:  Mol Neurobiol       Date:  2007-04       Impact factor: 5.590

2.  The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats.

Authors:  Svetlana Semenova; Athina Markou
Journal:  Eur Neuropsychopharmacol       Date:  2010-06-03       Impact factor: 4.600

3.  The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. (Rapid communication).

Authors:  P Martin; N Waters; A Carlsson; M L Carlsson
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 4.  Preclinical models of antipsychotic drug action.

Authors:  José L Moreno; Javier González-Maeso
Journal:  Int J Neuropsychopharmacol       Date:  2013-06-10       Impact factor: 5.176

Review 5.  "Selective" serotonin 5-HT2A receptor antagonists.

Authors:  Austen B Casey; Meng Cui; Raymond G Booth; Clinton E Canal
Journal:  Biochem Pharmacol       Date:  2022-04-04       Impact factor: 6.100

6.  Potentiation of excitatory serotonergic responses by MK-801 in the medial prefrontal cortex.

Authors:  Benoit Labonte; Francis Rodriguez Bambico; Gabriella Gobbi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.